Cardiome Pharma (CRME) Jumps on U.K. Nod

Cardiome Pharma Corp. CRME shares galloped 3.8% to $9.61,on word that the Secretary of State for the U.K. Department of Health has approved pricing for BRINAVESS® (vernakalant hydrochloride). The approved amount represents a maximum price per vial of BRINAVESS® in the United Kingdom. It is consistent with pricing in other territories and Cardiome's economic forecasts. Share volume was 14,700
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!